Aprea Therapeutics (Aprea Therapeutics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aprea Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-3.74 Mil. Aprea Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Aprea Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Aprea Therapeutics's current FCF Yield % is -42.72%.

The historical rank and industry rank for Aprea Therapeutics's FCF Margin % or its related term are showing as below:

APRE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -149.8
* Ranked among companies with meaningful FCF Margin % only.

Aprea Therapeutics FCF Margin % Historical Data

The historical data trend for Aprea Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics FCF Margin % Chart

Aprea Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Aprea Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aprea Therapeutics's FCF Margin %

For the Biotechnology subindustry, Aprea Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprea Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's FCF Margin % falls into.

Aprea Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aprea Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-12.271	/	0
	=	%

Aprea Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.74	/	0
	=	%

Aprea Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprea Therapeutics (Aprea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Executives

Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107